Karuna's KarXT could have a major competitive edge for schizophrenia treatment, says analyst

18 August 2022

US clinical-stage biotech firm Karuna Therapeutics (Nasdaq: KRTX) recently announced positive top-line results from the Phase III EMERGENT-2 trial of KarXT (xanomeline + trospium chloride) in acutely psychotic hospitalized adult patients with schizophrenia.

According to GlobalData, if KarXT continues to show success within the EMERGENT trial program as a monotherapy, as well as in the ongoing ARISE trial as an adjunctive to traditional antipsychotics, the drug could have a major competitive edge over current atypical antipsychotics, particularly pricey, later-generation products.

The data and analytics company notes that Karuna will need to replicate its findings in its three ongoing EMERGENT trials in order to confirm that the drug can improve both positive and negative symptoms of schizophrenia, while not being associated with common side-effects of antipsychotics including weight gain, sedation, and movement disorders.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK